Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.26 (
GSK
)
6,788
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Delta-catenin
was first identified because of its interaction with presenilin-1, and its aberrant expression has been reported in various human tumors and in patients with Cri-du-Chat syndrome, a form of mental retardation. However, the mechanism whereby
delta-catenin
is regulated in cells has not been fully elucidated. We investigated the possibility that glycogen-synthase kinase-3 (GSK-3) phosphorylates
delta-catenin
and thus affects its stability. Initially, we found that the level of
delta-catenin
was greater and the half-life of
delta-catenin
was longer in
GSK
-3beta(-/-) fibroblasts than those in
GSK
-3beta(+/+) fibroblasts. Furthermore, four different approaches designed to specifically inhibit
GSK
-3 activity, i.e.
GSK
-3-specific chemical inhibitors, Wnt-3a conditioned media, small interfering RNAs, and
GSK
-3alpha and -3beta kinase dead constructs, consistently showed that the levels of endogenous
delta-catenin
in CWR22Rv-1 prostate carcinoma cells and primary cortical neurons were increased by inhibiting
GSK
-3 activity. In addition, it was found that both
GSK
-3alpha and -3beta interact with and phosphorylate
delta-catenin
. The phosphorylation of DeltaC207-
delta-catenin
(lacking 207 C-terminal residues) and T1078A
delta-catenin
by
GSK
-3 was noticeably reduced compared with that of wild type
delta-catenin
, and the data from liquid chromatography-tandem mass spectrometry analyses suggest that the Thr(1078) residue of
delta-catenin
is one of the
GSK
-3 phosphorylation sites. Treatment with MG132 or ALLN, specific inhibitors of proteosome-dependent proteolysis, increased
delta-catenin
levels and caused an accumulation of ubiquitinated
delta-catenin
. It was also found that
GSK
-3 triggers the ubiquitination of
delta-catenin
. These results suggest that
GSK
-3 interacts with and phosphorylates
delta-catenin
and thereby negatively affects its stability by enabling its ubiquitination/proteosome-mediated proteolysis.
...
PMID:GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis. 1970 5
Through a multiprotein complex,
glycogen synthase kinase-3beta
(GSK-3beta) phosphorylates and destabilizes beta-catenin, an important signaling event for neuronal growth and proper synaptic function. delta-Catenin, or NPRAP (CTNND2), is a neural enriched member of the beta-catenin superfamily and is also known to modulate neurite outgrowth and synaptic activity. In this study, we investigated the possibility that
delta-catenin
expression is also affected by
GSK
-3beta signaling and participates in the molecular complex regulating beta-catenin turnover in neurons. Immunofluorescent light microscopy revealed colocalization of
delta-catenin
with members of the molecular destruction complex:
GSK
-3beta, beta-catenin, and adenomatous polyposis coli proteins in rat primary neurons.
GSK
-3beta formed a complex with
delta-catenin
, and its inhibition resulted in increased
delta-catenin
and beta-catenin expression levels. LY294002 and amyloid peptide, known activators of
GSK
-3beta signaling, reduced
delta-catenin
expression levels. Furthermore,
delta-catenin
immunoreactivity increased and protein turnover decreased when neurons were treated with proteasome inhibitors, suggesting that the stability of
delta-catenin
, like that of beta-catenin, is regulated by proteasome-mediated degradation. Coimmunoprecipitation experiments showed that
delta-catenin
overexpression promoted
GSK
-3beta and beta-catenin interactions. Primary cortical neurons and PC12 cells expressing
delta-catenin
treated with proteasome inhibitors showed increased ubiquitinated beta-catenin forms. Consistent with the hypothesis that
delta-catenin
promotes the interaction of the destruction complex molecules, cycloheximide treatment of cells overexpressing
delta-catenin
showed enhanced beta-catenin turnover. These studies identify
delta-catenin
as a new member of the
GSK
-3beta signaling pathway and further suggest that
delta-catenin
is potentially involved in facilitating the interaction, ubiquitination, and subsequent turnover of beta-catenin in neuronal cells.
...
PMID:Delta-catenin/NPRAP: A new member of the glycogen synthase kinase-3beta signaling complex that promotes beta-catenin turnover in neurons. 2062 42